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c-Abl
BCR-ABL











































































































































































































































Patients	(n)	 283	 282	 281	
OS	(%)a	 95.2	 98.1	 98.5	
PFS	(%)b	 94.7	 96.9	 98.3	
EFS	(%)b	 93.1	 95.3	 97.4	
MMR	(%)b	 53	 73	 70	
MR4	(%)b	 26	 50	 44	
Progression	to	AP/BC	(%)b	 95.2	 99.3	 98.7	
a	Overall	Survival	including	only	CML	related	deaths.	
b	Percentages	are	estimated	by	Kaplan–Meier	analysis.			
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2010)or	nilotinib(Saglio	et	al.,	2010),	as	well	as	nausea	and	vomiting.		However,	for	dasatinib,	the	rates	of	pleural	effusion	are	higher	than	in	patients	treated	with	other	TKIs	and	can	cause	discontinuation	of	treatment	in	some	patients.		As	already	described,	bosutinib	has	a	high	incidence	of	severe	diarrhoea	that	causes	many	patients	to	switch	TKI	treatment,	and	ponatinib	patients	have	a	high	level	of	severe	cardiovascular	complications	compared	to	all	other	TKIs.			 	

























































































































































	 LENGTH	(bp)	 LENGTH	(aa)	 BIOTYPE	
1	(CIP2A-1a)*	 4075	 905	 Protein	Coding	
2	(CIP2A-1b)*	 3877	 746	 Protein	Coding	
3	 2764	 121	 Nonsense-mediated	decay	
4	 654	 48	 Nonsense-mediated	decay	
5	 2014	 -	 Processed	Transcript	
6	 11	 -	 Retained	intron	*Transcript	variant	investigated	in	Chapter	6.				 	























































a. Chapter	3:Biomarker	status	of	CIP2A:	i. First	I	aimed	to	classify	my	patient	cohorts	according	to	high/low	CIP2A	protein	level	at	diagnosis,	using	flow	cytometry.	ii. Correlations	between	basal	CIP2A	protein	and	clinical	outcomes	were	investigated	and	compared	to	previous	work	on	imatinib-treated	CML.		The	aim	was	to	study	the	potential	biomarker	role	of	CIP2A	in	second	generation	TKI	treated	CML.	
b. Chapter	4:Comparative	effects	of	TKIs	on	the	CIP2A/PP2A	pathway:	i. Using	patient	follow-up	samples,	I	investigated	the	effects	of	long-term	in	vivo	TKI	therapy	on	various	parts	of	the	CIP2A/PP2A	pathway.	ii. After	designing	a	short-term	in	vitro	TKI	culture,	I	investigated	short-term	effects	of	treatments	upon	various	parts	of	the	





























































































CIP2A	(Santa	Cruz	Biotechnology	(SCBT),	Dallas,	TX,	USA)	 16µg/ml	 Mouse	IgG1	 Alexa	Fluor	488	Mouse	
PP2A	(Millipore)	 100µg/ml	 Mouse	IgG1	 Alexa	Fluor	488	Mouse	
pY307-PP2A	(Abcam,	Cambridge,	Cambridgeshire,	UK)	 9µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
SET	(I2PP2A)	(SCBT)	 20µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
SETBP1	(SCBT)	 20µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
JAK2	(SCBT)	 20µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
CrKL	(SCBT)	 10µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
pY207-CrKL	(Cell	Signalling	Technology	(CST),	Danvers,	MA,	USA)	 10µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
c-Myc	(CST)	 20µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit	
c-Myc	pS62	(Abcam)	 10µg/ml	 Rabbit	IgG	 Alexa	Fluor	488	Rabbit		Mouse	IgG1	(BD	Biosciences;	#349040)	Rabbit	IgG	(Research	&	Development	(R&D)	Systems,	Abingdon,	Oxfordshire,	UK;	AB-105-C)	Alexa	Fluor	488	Goat	Anti-Mouse	IgG	(H+L)	(Life	Technologies,	Paisley,	Renfrewshire,	UK;	A-11001)	Alexa	Fluor	488	Goat	Anti-Rabbit	IgG	(H+L)	(Life	Technologies;	A-11001)		


























Final	Concentration	(µg/ml)	 BSA	Stock	(10µg/ml)	 RIPA	Buffer	0	 (1000µl	ddH2O)	 	0.5	 50µl	 950µl	1	 100µl	 900µl	1.5	 150µl	 850µl	2	 200µl	 800µl	2.5	 250µl	 750µl	3	 300µl	 700µl		
2.6.3.	Gel	Electrophoresis	
Prior	to	loading,	samples	were	diluted	to	20µg/ml	in	double	strength	SDS	buffer	(DSSB)	and	heated	at	95°C	for	5	minutes.		A	12%	polyacrylamide	gel	(4ml	resolving	gel	buffer,	8ml	acrylamide,	4ml	H2O,	75µl	of	10%	ammonium	persulphate	(APS),	15µl	tetramethylethylenediamine	(TEMED;	Sigma-Aldrich))	was	assembled	between	two	glass	plates	and	left	until	polymerisation	occurred	(gel	has	set).		A	5%	polyacrylamide	stacking	gel	was	then	assembled	on	top	(1.5ml	stacking	buffer,	1ml	acrylamide,	3.5ml	H2O,	50µl	of	10%	APS,	15µl	TEMED),	with	a	10-well	comb	used	to	create	sample	wells.		Protein	samples	were	loaded	alongside	a	pre-stained	protein	ladder	(Bio-Rad),	and	then	the	samples	were	run	at	35mA	per	gel	for	approximately	90	minutes.			



















































c-Myc	pS62	(Abcam)	 120ng/ml	 Rabbit	IgG		Anti-mouse	IgG,	HRP-linked	Antibody	(CST;	#7076)	Anti-rabbit	IgG,	HRP-linked	Antibody	(CST;	#7074)	 	
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25°C	for	5	minutes.		Superscript	II	reverse	transcriptase	kit	(200µg/µl)	(Invitrogen)	was	added	and	tubes	incubated	sequentially,	at	25°C	for	10	minutes,	42°C	for	60	minutes	then	finally	70°C	for	15	minutes	to	stop	the	reaction.		The	acquired	cDNA	could	be	used	immediately,	or	stored	long-term	at	-20°C.			 	



































































































































































	 Total	 Imatinib	treated	 2G	TKI	treated	
No.	of	patients	 69	 41	 28	
Average	age	(range)	 50	(19-75)	 48	(19-74)	 54	(24-75)	
Sex	M/F	 34/35	 23/18	 11/17	
HIGH	CIP2A	 22	 12	 10	
LOW	CIP2A	 47	 29	 18		
It	should	be	noted	that	the	high	rate	of	blast	crisis	patients	within	my	samples	is	due	to	deliberate	selection.		It	is	therefore	not	possible	from	these	data	to	comment	on	the	incidence	of	high	CIP2A	in	a	general	CML	population.					
	









































































































































































































Diagnosis 12 months Diagnosis 12 months
Diagnosis 12 months Diagnosis 12 months
p=0.011
Diagnosis 12 months Diagnosis 12 months
p=0.011
A. CIP2A
G. c-Myc S62F. c-Myc
E. JAK2D. SET
C. pY307-PP2AB. PP2A



















G. c-Myc S62F. c-Myc
E. JAK2D. SET
C. pY307-PP2AB. PP2A
















































(Low=0,	High=1)	070	 F	 73	 Low	071	 F	 54	 Low	072	 F	 68	 Low	073	 M	 69	 Low	074	 M	 55	 Low	075	 M	 54	 Low	076	 M	 34	 Low	077	 F	 35	 High	078	 F	 27	 High	079	 F	 62	 High	080	 F	 52	 High	081	 M	 29	 High	082	 M	 69	 High		
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Here,	the	immediate	molecular	effects	of	ponatinib	on	the	CIP2A/PP2A	pathway	are	investigated	in	treatment-naïve	CML	samples	and	a	small	study	of	six	patients	treated	with	ponatinib	following	other	TKI	failures	are	individually	analysed.			 	











































































































































































































































































































































































































































































































































































































































083	 F	 63	 Y	(abl1	KD)	 Low	 CCR	/	19	
084	 F	 74	 N	 High	 CCR	/	2	
085	 M	 76	 Y	(abl1	KD)	 High	 NO	RESPONSE	
086	 M	 61	 Y	(T315I)	 Low	 NO	RESPONSE	
087	 F	 69	 Y	(abl1	KD)	 Low	 DIED	/	6	
088	 M	 60	 N	 High	 DIED	/	1		
	
	 	











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
CIP2A-1a         177 ...............AAAAAAAGCGCGGCGAAAGCTAAAGGCCGGCGCACGCTGGGCGGTGGTGGTCCCTAAGCCGGGCCGCGGCCGGTGCA    269 
CIP2A-1b         177 ...............-----------------------------------------------------------------------------    269 
 
CIP2A-1a         270 ATGGACTCCACTGCCTGCTTGAAGTCCTTGCTCCTGACTGTCAGTCAGTACAAAGCCGTGAAGTCAGAGGCGAACGCCACTCAGCTTTTGCG    362 
CIP2A-1b         270 --------------------------------------------------------------------------------------------    362 
 
CIP2A-1a         363 GGCACTTGGAG.................................................................................    455 
CIP2A-1b         363 -----------.................................................................................    455 
 
 
CIP2A-1a        3881 ...............CCTTAACTTCTGAGCTCACCTATTGTCTTTGGGAAGAAGCAGAAGGAATAATCCCATAACTACCCTCTGGGCTTCAT   3959 
CIP2A-1b        3881 ...............CCTTAACTTCTGAGCTCACCTATTGTCTTTGGGAAGAAGCAGAAGGAATAATCCCATAACTACCCTCTGGGCTTCAT   3959 
 
CIP2A-1a        3960 TTTTCATTCTCCTCCCTCAAA...................................................GTAATTTCTGGACAGAAACT   4052 
CIP2A-1b        3960 TTTTCATTCTCCTCCCTCAAA...................................................GTAATTTCTGGACAGAAACT   4052 
 
CIP2A-1a        4053 CACACGACTATTTACATCAAATCAGATATTAACAAGTGAATGCTTGAGTTGCCTTGTAGAGCTACTTGAAGACCCCAACATAAGTGCTTCAC   4145 
CIP2A-1b        4053 CACACGACTATTTACATCAAATCAGATATTAACAAGTGAATGCTTGAGTTGCCTTGTAGAGCTACTTGAAGACCCCAACATAAGTGCTTCAC   4145 
  
CIP2A-1a        4146 TGATCTTAAGTATTATCGGTTTGCTGTCTCAACTAG........................................................   4238 
CIP2A-1b        4146 TGATCTTAAGTATTATCGGTTTGCTGTCTCAACTAG........................................................   4238 
 
 
CIP2A-1a        8118 ...............TCAATCTTCTGAAGATGAGTTAAAAATGCCTTGTCTAGGATTATTGGCAAATCTTTGTCGGCACAATCTTTCTGTTC   8210 
CIP2A-1b        8118 ...............TCAATCTTCTGAAGATGAGTTAAAAATGCCTTGTCTAGGATTATTGGCAAATCTTTGTCGGCACAATCTTTCTGTTC   8210 
 
CIP2A-1a        8211 AAACGCACATAAAGACATTG........................................................................   8210 










1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21



























53	 54	 55	 56	 57	 58	 53	 54	 55	 56	 57	 58	 53	 54	 55	 56	 57	 58	






















025	 M	 LOW	 Optimal	065	 M	 LOW	 Optimal	011	 F	 LOW	 Optimal	012	 F	 LOW	 Optimal	066	 M	 LOW	 Optimal	001	 F	 LOW	 Optimal	028	 M	 LOW	 Failure	062	 F	 LOW	 Optimal	007	 F	 LOW	 Optimal	018	 M	 LOW	 Sub-Optimal	017	 M	 LOW	 Optimal	051	 M	 LOW	 Optimal	061	 F	 LOW	 Optimal	014	 F	 LOW	 Optimal	045	 F	 LOW	 Optimal	029	 M	 LOW	 Optimal	043	 F	 LOW	 Sub-Optimal	059	 M	 HIGH	 Optimal	068	 F	 HIGH	 Optimal	
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053	 F	 HIGH	 Optimal	031	 F	 HIGH	 Sub-Optimal	056	 F	 HIGH	 Optimal	055	 F	 HIGH	 Optimal	032	 F	 HIGH	 Failure	041	 M	 HIGH	 Optimal	033	 M	 HIGH	 Blast	Crisis	057	 M	 HIGH	 Optimal	058	 M	 HIGH	 Optimal		
	
	 	




































































































































































































































































































































































CpG island CpG island
3.5K
















1	 N/A	 Normal	 F	 N/A	 N/A	
2	 N/A	 Normal	 F	 N/A	 N/A	
3	 N/A	 Normal	 F	 N/A	 N/A	
4	 N/A	 Normal	 F	 N/A	 N/A	
5	 N/A	 Normal	 M	 N/A	 N/A	
6	 N/A	 Normal	 M	 N/A	 N/A	
7	 N/A	 Normal	 M	 N/A	 N/A	
8	 N/A	 Normal	 M	 N/A	 N/A	
9	
N/A	 Cell	line	(K562)	 N/A	 N/A	 N/A	
10	
N/A	 Cell	line	(KCL22)	 N/A	 N/A	 N/A	
11	
N/A	 Cell	line	(LAMA84)	 N/A	 N/A	 N/A	
12	
N/A	 Cell	line	(U937)	 N/A	 N/A	 N/A	
13	
N/A	 Cell	line	(HEK293)	 N/A	 N/A	 N/A	
14	
N/A	 Cell	line	(KY01)	 N/A	 N/A	 N/A	
15	 022	 Patient	 M	 Diagnosis	 Optimal	
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16	 001	 Patient	 F	 Diagnosis	 Optimal	
17	 003	 Patient	 F	 Diagnosis	 Optimal	
18	 006	 Patient	 F	 Diagnosis	 Optimal	
19	 024	 Patient	 M	 Diagnosis	 Optimal	
20	 021	 Patient	 M	 Diagnosis	 Optimal	
21	 012	 Patient	 F	 Diagnosis	 Optimal	
22	 020	 Patient	 M	 Diagnosis	 Optimal	
23	 013	 Patient	 F	 Diagnosis	 Optimal	
24	 009	 Patient	 F	 Diagnosis	 Optimal	
25	
043	 Patient	 F	 Diagnosis	 Sub-Optimal	
26	
018	 Patient	 M	 Diagnosis	 Sub-Optimal	
27	
031	 Patient	 F	 Diagnosis	 Sub-Optimal	
28	
089	 Patient	 M	 Diagnosis	 Sub-Optimal	
29	
090	 Patient	 M	 Diagnosis	 Sub-Optimal	
30	
091	 Patient	 M	 Diagnosis	 Sub-Optimal	
31	 032	 Patient	 F	 Diagnosis	 Failure	
32	 092	 Patient	 F	 Diagnosis	 Failure	
33	 093	 Patient	 F	 Diagnosis	 Failure	
34	 094	 Patient	 F	 Diagnosis	 Failure	
35	 095	 Patient	 M	 Diagnosis	 Failure	
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36	 096	 Patient	 M	 Diagnosis	 Failure	
37	 097	 Patient	 M	 Diagnosis	 Failure	
38	 098	 Patient	 M	 Diagnosis	 Failure	
39	 099	 Patient	 M	 Diagnosis	 Failure	
40	 100	 Patient	 M	 Diagnosis	 Failure	
41	 030	 Patient	 F	 Diagnosis	 Blast	Crisis	
42	 101	 Patient	 F	 In	BC	 Blast	Crisis	
43	 033	 Patient	 M	 Diagnosis	 Blast	Crisis	
44	 034	 Patient	 M	 Diagnosis	 Blast	Crisis	
45	 035	 Patient	 M	 Diagnosis	 Blast	Crisis	


















































48	 49	 50	 51	 52	
1%		 1%		 1%		 1%		 1%		40%		 40%		 40%		 40%		 40%		










1	 2	 3	 4	 5	 7	 8	 9	
Meth	control	
(49)	





21	 22	 23	 24	 25	 26	 27	 28	
Meth	control	
36	 37	 38	 39	 40	 41	 42	 43	













































1	 2	 3	 4	 5	 6	 7	 8	 11	9	 12	10	 13	 14	 15	 16	 17	 18	 19	 20	 21	 22	 25	23	 24	
































































































































































001	 59	 F	 IM	 ALIVE	 N/81.53	 N/81.53	 OPTIMAL	 LOW	
002	 62	 F	 IM	 ALIVE	 N/24.85	 Y/24.85	 OPTIMAL	 LOW	
003	 35	 F	 IM	 ALIVE	 N/103.1	 Y/22.13	 OPTIMAL	 LOW	
004	 49	 F	 IM	 ALIVE	 N/41.92	 Y/45.3	 OPTIMAL	 LOW	
005	 54	 F	 IM	 ALIVE	 N/18.58	 Y/18.58	 OPTIMAL	 LOW	
006	 30	 F	 IM	 ALIVE	 N/84.99	 N/84.99	 OPTIMAL	 LOW	
007	 18	 F	 IM	 ALIVE	 N/76.01	 Y/22.39	 OPTIMAL	 LOW	
008	 68	 F	 IM	 ALIVE	 N/50.6	 N/50.6	 OPTIMAL	 LOW	
009	 55	 F	 IM	 ALIVE	 N/66.94	 N/66.94	 OPTIMAL	 LOW	
010	 23	 F	 IM	 ALIVE	 N/29.88	 Y/18.61	 OPTIMAL	 LOW	
011	 43	 F	 IM	 ALIVE	 N/34.98	 Y/34.98	 OPTIMAL	 LOW	
012	 45	 F	 IM	 ALIVE	 N/54.08	 N/54.08	 OPTIMAL	 LOW	
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013	 67	 F	 IM	 ALIVE	 N/34.95	 N/34.95	 OPTIMAL	 LOW	
014	 40	 F	 IM	 ALIVE	 N/17.62	 N/17.95	 OPTIMAL	 LOW	
015	 70	 F	 IM	 ALIVE	 N/11.54	 N/14.27	 OPTIMAL	 LOW	
016	 73	 M	 IM	 DEAD	 N/92.98	 N/92.98	 N/A	 LOW	
017	 59	 M	 IM	 ALIVE	 N/86.5	 N/86.5	 OPTIMAL	 LOW	
018	 47	 M	 IM	 ALIVE	 N/14.3	 Y/17.29	 SUB-OPTIMAL	 LOW	
019	 55	 M	 IM	 ALIVE	 N/86.37	 N/86.37	 OPTIMAL	 LOW	
020	 48	 M	 IM	 ALIVE	 N/82.09	 N/82.09	 OPTIMAL	 LOW	
021	 48	 M	 IM	 ALIVE	 N/24.92	 N/24.92	 OPTIMAL	 LOW	
022	 39	 M	 IM	 ALIVE	 N/42.12	 Y/25.78	 OPTIMAL	 LOW	
023	 72	 M	 IM	 ALIVE	 N/69.27	 N/69.27	 OPTIMAL	 LOW	
024	 47	 M	 IM	 ALIVE	 N/66.44	 Y/16.27	 OPTIMAL	 LOW	
025	 33	 M	 IM	 ALIVE	 N/68.42	 N/68.42	 OPTIMAL	 LOW	
026	 28	 M	 IM	 ALIVE	 N/14.79	 Y/14.79	 OPTIMAL	 LOW	
027	 24	 M	 IM	 ALIVE	 N/20.81	 Y/20.81	 OPTIMAL	 LOW	
028	 58	 M	 IM	 ALIVE	 N/9.01	 Y/9.04	 FAILURE	 LOW	
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029	 59	 M	 IM	 ALIVE	 N/15.88	 N/17.95	 OPTIMAL	 LOW	
030	 30	 F	 IM	 ALIVE	 Y/14.79	 Y/9.34	 BC	 HIGH	
031	 28	 F	 IM	 ALIVE	 N/15.98	 Y/15.98	 SUB-OPTIMAL	 HIGH	
032	 68	 F	 IM	 ALIVE	 N/9.9	 Y/9.9	 FAILURE	 HIGH	
033	 58	 M	 IM	 ALIVE	 Y/7.17	 Y/7.17	 BC	 HIGH	
034	 23	 M	 IM	 ALIVE	 Y/36.03	 Y/11.87	 BC	 HIGH	
035	 33	 M	 IM	 ALIVE	 Y/12.53	 Y/13.91	 BC	 HIGH	
036	 56	 M	 IM	 ALIVE	 Y/11.28	 Y/11.28	 BC	 HIGH	
037	 24	 M	 IM	 ALIVE	 Y/21.44	 Y/22.98	 BC	 HIGH	
038	 64	 M	 IM	 ALIVE	 Y/15.62	 Y/15.62	 BC	 HIGH	
039	 60	 M	 IM	 ALIVE	 Y/31.53	 N/31.53	 BC	 HIGH	
040	 32	 M	 IM	 ALIVE	 Y/15.19	 Y/15.19	 BC	 HIGH	
041	 45	 M	 IM	 ALIVE	 Y/23.18	 Y/23.18	 BC	 HIGH	
042	 69	 F	 DAS	 ALIVE	 N/54.12	 N/54.12	 OPTIMAL	 LOW	
043	 30	 F	 DAS	 ALIVE	 N/16.77	 Y/16.77	 SUB-OPTIMAL	 LOW	
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044	 24	 F	 DAS	 ALIVE	 N/44.48	 N/44.48	 OPTIMAL	 LOW	
045	 51	 F	 DAS	 ALIVE	 N/27.16	 N/27.16	 OPTIMAL	 LOW	
046	 62	 F	 DAS	 ALIVE	 N/23.93	 Y/12.79	 OPTIMAL	 LOW	
047	 58	 F	 DAS	 ALIVE	 N/12.66	 N/12.66	 OPTIMAL	 LOW	
048	 54	 M	 DAS	 ALIVE	 N/59.67	 N/59.67	 OPTIMAL	 LOW	
049	 43	 M	 DAS	 ALIVE	 N/23.7	 N/23.7	 OPTIMAL	 LOW	
050	 48	 M	 DAS	 ALIVE	 N/37.55	 N/37.55	 OPTIMAL	 LOW	
051	 48	 M	 DAS	 ALIVE	 N/21.14	 N/21.14	 OPTIMAL	 LOW	
052	 66	 M	 DAS	 ALIVE	 N/18.67	 N/18.67	 OPTIMAL	 LOW	
053	 54	 F	 DAS	 ALIVE	 N/44.02	 N/44.02	 OPTIMAL	 HIGH	
054	 47	 F	 DAS	 ALIVE	 N/43.73	 Y/31.89	 OPTIMAL	 HIGH	
055	 73	 F	 DAS	 ALIVE	 N/23.87	 N/23.87	 OPTIMAL	 HIGH	
056	 53	 F	 DAS	 ALIVE	 N/17.98	 N/17.98	 OPTIMAL	 HIGH	
057	 52	 M	 DAS	 ALIVE	 N/54.35	 N/54.35	 OPTIMAL	 HIGH	
058	 62	 M	 DAS	 ALIVE	 N/52.47	 N/52.47	 OPTIMAL	 HIGH	
059	 54	 M	 DAS	 ALIVE	 N/37.91	 N/37.91	 OPTIMAL	 HIGH	
060	 49	 F	 NIL	 ALIVE	 N/64.67	 N/64.67	 OPTIMAL	 LOW	
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061	 63	 F	 NIL	 ALIVE	 N/61.18	 N/61.18	 OPTIMAL	 LOW	
062	 53	 F	 NIL	 ALIVE	 N/60	 N/60	 OPTIMAL	 LOW	
063	 67	 F	 NIL	 ALIVE	 N/60.49	 N/60.49	 OPTIMAL	 LOW	
064	 46	 M	 NIL	 ALIVE	 N/58.82	 N/58.82	 OPTIMAL	 LOW	
065	 45	 M	 NIL	 ALIVE	 N/57.21	 N/57.21	 OPTIMAL	 LOW	
066	 64	 M	 NIL	 ALIVE	 N/8.81	 N/8.81	 OPTIMAL	 LOW	
067	 57	 F	 NIL	 ALIVE	 N/56.45	 N/56.45	 OPTIMAL	 HIGH	
068	 27	 F	 NIL	 ALIVE	 N/19.86	 N/19.86	 OPTIMAL	 HIGH	
069	 74	 F	 NIL	 ALIVE	 N/11.77	 N/11.77	 OPTIMAL	 HIGH	
070	 73	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
071	 54	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
072	 68	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
073	 69	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
074	 55	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
075	 54	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
076	 34	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 LOW	
077	 35	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
078	 27	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
240	|	P a g e 	
	
079	 62	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
080	 52	 F	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
081	 29	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
082	 69	 M	 N/A	 N/A	 N/A	 N/A	 N/A	 HIGH	
083	 63	 F	 N/A	 ALIVE	 N/A	 N/A	 N/A	 LOW	
084	 74	 F	 N/A	 ALIVE	 N/A	 N/A	 N/A	 HIGH	
085	 76	 M	 N/A	 ALIVE	 N/A	 N/A	 N/A	 HIGH	
086	 61	 M	 N/A	 ALIVE	 N/A	 N/A	 N/A	 LOW	
087	 69	 F	 N/A	 DEAD	 N/A	 N/A	 N/A	 LOW	
088	 60	 M	 N/A	 DEAD	 N/A	 N/A	 N/A	 HIGH	
089	 55	 M	 N/A	 ALIVE	 N/A	 N/A	 SUB-OPTIMAL	 LOW	
090	 24	 M	 N/A	 ALIVE	 N/A	 N/A	 SUB-OPTIMAL	 HIGH	
091	 39	 M	 N/A	 ALIVE	 N/A	 N/A	 SUB-OPTIMAL	 HIGH	
092	 45	 F	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 LOW	
093	 68	 F	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 LOW	
094	 69	 F	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
095	 70	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
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096	 58	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
097	 56	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
098	 49	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
099	 62	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
100	 63	 M	 N/A	 ALIVE	 N/A	 N/A	 FAILURE	 HIGH	
101	 60	 F	 N/A	 DEAD	 N/A	 N/A	 BC	 HIGH	
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